Biotech Mergers: Evaluating Risk, Reporting, and Integration of Growth Strategies : Gilead’s Acquisition of Immunomedics: Risk and a Growth Strategy . AEJ [Internet]. 2025 Mar. 20 [cited 2026 Aug. 15];33. Available from: https://www.aejournal.com/ojs/index.php/aej/article/view/1044